^
Association details:
| Biomarker: | STK11 expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | SB202190 (MAPK inhibitor, p38 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38
Excerpt:
Collectively, our data show that STK11 is a key factor involved in the early phases of prostate carcinogenesis, and suggest that it might be used as a predictive marker of therapeutic response to MAPK/p38 inhibitors in PCa patients.
DOI:
10.1080/15548627.2015.1091910
